NewsWhat's your challenge?
All the latest news and information from Adelphi Values.
The team at Adelphi Values | PROVE™ has been getting involved in environmentally-friendly initiatives in honour of World Earth Day which took place on Sunday 22nd April 2018.
Earth Day Network, the organisation behind World Earth Day, has chosen the theme ‘End Plastic Pollution’ for 2018. Plastic pollution is one of the most important global problems that we face today, impacting the environment, our oceans, animal life, and our health and well-being through the resultant presence of plastic particles in our food.
As part of a global effort to reduce the use of plastics (primarily single-use plastics) and encourage increased recycling, our team implemented a range of initiatives including reducing our use of plastic cups and packaging, avoiding disposable plastic wherever possible, and other environmentally-friendly challenges.
Together we can all make a difference and help to protect our Earth!
Each Christmas, instead of sending cards in the post, we at Adelphi Group provide our colleagues, partners and associates with the opportunity to nominate a worthy cause for us to donate to on their behalf.
In 2017, we supported Unicef to help make a difference for children all over the world. We received nominations in their droves, and are now delighted to confirm that as a result, we have been able to provide:
These donations were part of Adelphi Group’s ongoing charity program which focuses on both local and global health and wellness charities. We are immensely proud to support these life-saving initiatives.
If you would like to donate to any of the above wonderful causes, please visit https://www.unicef.org.uk/
Adelphi Values applauds Revance Therapeutics in their demonstration of RT002 treatment success in their Pivotal SAKURA Phase 3 Trials for Glabellar Lines. Please see the announcement for full reporting: http://investors.revance.com/releasedetail.cfm?ReleaseID=1050685
Revance’s RT002 demonstrated positive top-line results in both SAKURA 1 and SAKURA 2 in patient and clinician reported outcomes associated with wrinkle severity as well as superiority in terms of patient rated treatment satisfaction. In this program, the Adelphi Values PCO team worked with Revance in advancing the primary and secondary outcomes tools in SAKURA 1 and SAKURA 2 as well as building the regulatory documentation and evidence base to support their use as primary and secondary endpoints. According to Alan Shields, Vice-President of Adelphi Values, “this is a very excellent milestone for Revance and aesthetic medicine as RT002 reflects a novel approach and could offer patients a different and long-acting treatment option they don’t currently have available to them.” He further indicated, “I’m very proud of the contributions that Ben Banderas, Catherine Foley, and the rest of our Adelphi Values team had in this program. Revance is a wonderful and dedicated group of people with whom to work and we send them our congratulations on achieving this excellent milestone.”
Adelphi Values | PROVE™ will be leading a podium presentation entitled ‘Differences in vaccine pricing between high‑income and low‑income markets’. Covering 7 different disease areas, the presentation will give an overview of market access for vaccines in lower income countries, discuss the reasons behind the huge price difference and the contributing factors, and also the role of organisations such as PAHO and GAVI in addressing market access. The presentation will be taking place at 16:45-17:45 on Tuesday 7th November in room Forth (Armadillo).
We will also have six scientific poster presentations, as well as a wide range of presentations from the wider Adelphi team, on display across the 3 days. The diverse research covers a range of therapy areas, healthcare products and services including immunotherapies, vaccines, orphan drugs, medical devices, maternal screening/treatments, cost-effectiveness assessments, patient preferences, real-world treatment experiences and quality of life. A full list of the presentations can be found here.
Adelphi Values | PROVE™ will also be exhibiting alongside the Adelphi Values Patient Centered Outcomes practice and sister company Adelphi Real World. Members of our Real World, Values and Outcomes team will be on hand to discuss the presentations in more detail or answer any questions you may have. Come and visit us at booth 301 – we look forward to seeing you!
The 20th Annual European Congress of ISPOR (the International Society of Pharmacoeconomics and Outcomes Research) takes place from 4th-8th November 2017 in Glasgow, Scotland, and is recognised as the leading scientific and educational organisation for outcomes research in healthcare decisions, hosting many of the foremost experts from around the world.
To set up a meeting with us at ISPOR, or if you would like further information on our presentations or on any of our broader healthcare value consultancy solutions, please contact us or alternatively email email@example.com.
On Friday 28th July 2017 over 50 staff from the Adelphi Group took part in a 7 Peak Challenge – a marathon 26 mile walk through the Derbyshire and Cheshire hills located close to our UK head office. Despite the torrential rain and strong winds, everyone was proud to take part in the 9-hour hike to help raise money for two wonderful causes, The Alzheimer’s Society and East Cheshire Hospice.
The Alzheimer’s Society is working to transform the landscape of dementia and to create a society where those affected by dementia are supported and accepted, able to live in their community without fear or prejudice.
The East Cheshire Hospice is a local organisation which provides essential care, support and compassion to adults facing life limiting illnesses.
If you would like to support the fundraising, please visit the following Just Giving pages:
The Alzheimer’s Society: http://www.justgiving.com/Adelphi-Group
East Cheshire Hospice: http://www.justgiving.com/Adelphi-Group2
Adelphi Values will be presenting and exhibiting at the 22nd Annual International Meeting of ISPOR, the International Society of Pharmacoeconomics and Outcomes Research, which takes place from 20th‑24th May 2017 in Boston, MA, USA.
Team members from Adelphi Values PROVE, Patient-Centered Outcomes and our sister company Adelphi Real World will be on hand at booths 612/614 to discuss the wide range of tailored Real World, Value and Outcomes solutions we offer to overcome the challenges of developing and commercialising healthcare products and services.
In addition, team members from both our UK and US offices will be presenting a workshop and a forum as well as a wide range of posters across a variety of therapy areas and topics including oncology, rare genetic diseases, ophthalmology and endocrinology.
The workshop is entitled ‘Conducting qualitative ‘exit’ interviews following clinical trials or observational studies: a valuable method for understanding the patient experience, informing measurement strategy, and aiding interpretation of patient-reported outcomes’. This workshop will be co-presented by Rob Arbuckle, Managing Director, Patient-Centered Outcomes UK, on Wednesday 24th May at 8:45am in Sheraton-Back Bay CD – 2nd floor. Through the use of examples from a range of disease areas, this workshop will stimulate discussion regarding the value generated by ‘exit’ interview data and ways to overcome common challenges and limitations.
The forum presentation is entitled ‘How does measurement of multiple medication adherence differ between chronic diseases?’ and will be presented on Monday 22nd May at 6:15pm by the ISPOR Medication Adherence Special Interest Group, with Bryan Bennett, Director, Patient-Centered Outcomes UK, as one of the three speakers. This interactive forum will look at the most common methods used to calculate adherence to multiple medications (AtMM), an assessment of the studies carried out, and the need to evaluate the differences between diseases in evaluating and deriving multiple adherence as well as determining the implications of using different measurements. Participants will be encouraged to contribute their experience and will have the opportunity to discuss and suggest potential solutions to the issues.
With thousands of attendees from around 80 countries, ISPOR is recognised as the leading scientific and educational organisation for outcomes research in healthcare decisions and hosts many of the foremost experts around the world. This year’s event is entitled ‘Evidence and Value in a Time of Social and Policy Change’ and provides a great platform for knowledge sharing.
If you would like further information on our presentations at ISPOR or on any of our broader PROVE or Patient-Centered Outcomes solutions, please contact us or alternatively come and speak to a member of our team at booths 612/614 – we look forward to seeing you!
Our 2016 Adelphi Group Client Seasons Greetings charity initiative for Unicef received a fantastic response from our clients and partners, resulting in the following donations:
This initiative was part of our ongoing programme of charity initiatives which are widespread across our Group – we would like to sincerely thank everybody who donated to this worthy cause!
Adelphi Values has been invited to present at the DIA’s Advancing the Science of Study Endpoints meeting to be held in Washington DC on Dec 5 and 6. The purpose of the meeting is to assemble health outcomes experts to examine global strategies for selecting study endpoints and the impact of endpoints during the analysis of clinical evidence for various types of drug approval processes.
Alan Shields, PhD, Vice-president of our US Patient-Centered Outcomes practice, will be presenting in a session entitled, Meaningful Score Changes to Establish Endpoint Definitions.
Meet our team presenting and exhibiting at the 19th Annual European Congress at ISPOR, the International Society of Pharmacoeconomics and Outcomes Research, which takes place from 31st October to 2nd November 2016 in Vienna, Austria.
Our workshop this year is entitled ‘Measuring multiple medication adherence – which measure when?’ and will be held at 1:45-2:45pm in Hall F2 (L0). Bryan Bennett, Director in Patient-Centered Outcomes at Adelphi Values, will be presenting alongside three others. The workshop explores the various methods used to estimate adherence to multiple medications (AtMM), presenting the methods currently employed in the AtMM literature followed by a discussion of pros and cons of the methods and the calculations used to derive the measure of adherence.
In addition, we have a variety of scientific poster presentations which cover therapy areas including oncology, dermatology, the respiratory system and acute pain along with topics such as psychometric analyses of clinical outcome assessments (COAs) and clinical trials.
With thousands of attendees from around 80 countries, ISPOR is recognised as the leading scientific and educational organisation for outcomes research in healthcare decisions and hosts many of the foremost experts around the world. This year’s event is entitled ‘Managing Access to Medical Innovation: Strengthening the Methodology-Policy Nexus’ and provides a great platform for knowledge sharing.
Our exhibition booths are numbers 504/505, with our sister company Adelphi Real World alongside us at 503. Come and visit our team at our booth – we look forward to seeing you!
If you would like further information on our presentations at ISPOR or on any of our broader healthcare value consultancy or patient-centered research solutions, please contact us or alternatively email firstname.lastname@example.org
In October, our US team will be taking part in JDRF One Walk, to raise money for the Juvenile Diabetes Research Foundation (JDRF). Covering 5km around Boston, the JDRF flagship event aims to raise awareness of type1 diabetes (T1D), and funds toward achieving their mission, “to create a world without T1D”. 1.25 million Americans are currently living with T1D and the prevalence is increasing.
As our chosen US charity for 2016, we supported JDRF at the ISPOR conference in Washington DC earlier this year, and our team are looking forward to taking part in the walk and continuing our support of this worthy cause.
JDRF is the leading global organization funding T1D research and with a mission to “accelerate life-changing breakthroughs to cure, prevent and treat Type 1 Diabetes (T1D) and its complications”, and currently funding more than 50 human clinical trials.
For more information on JDRF or how to get involved, please visit the JDRF One Walk website.
Don’t be a stranger, you might have a simple enquiry or need our help. Whatever the reason, visit our contact page to find out who can help you.
Our practices page will help you better understand our expertise and how we can help.